Fortress Biotech, Inc. (FBIOP)
| Market Cap | 86.70M +87.3% |
| Revenue (ttm) | 66.16M +14.5% |
| Net Income | 119.20M |
| EPS | 3.86 |
| Shares Out | 33.22M |
| PE Ratio | 0.73 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,128 |
| Open | 19.05 |
| Previous Close | 19.42 |
| Day's Range | 19.05 - 19.62 |
| 52-Week Range | 6.27 - 21.43 |
| Beta | 1.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About FBIOP
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycl... [Read more]
News
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on dev...
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeuti...
Fortress Biotech Slides: Investor presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Fortress Biotech Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with two motions: electing directors for the next term and ratifying KPMG as auditors for 2026. Both motions were approved by shareholders, concluding the formal business.
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference
The company leverages a scalable, diversified model to acquire and develop clinical-stage medicines, generating value through royalties, equity, and milestones. Recent monetizations and FDA approvals have strengthened cash flow, while AI-driven asset identification and a robust pipeline position the company for continued growth.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on d...
Fortress Biotech price target raised to $5 from $4.50 at Alliance Global
Alliance Global raised the firm’s price target on Fortress Biotech (FBIO) to $5 from $4.50 and keeps a Buy rating on the shares, citing increased value from its cash balance…
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 mill...
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position inc...
Fortress Biotech Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth year-over-year, driven by EMROSI’s strong performance and improved profitability. EMROSI prescriptions and revenue per script increased, with expanded payer access and new product launches planned for 2026.
Fortress Biotech Quarterly report: Q1 2026
Fortress Biotech has published its Q1 2026 quarterly earnings report on May 13, 2026.
Fortress Biotech Earnings release: Q1 2026
Fortress Biotech released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Fortress Biotech Proxy statement: Proxy filing
Fortress Biotech filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Fortress Biotech Proxy statement: Proxy filing
Fortress Biotech filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 mill...
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 ...
Fortress Biotech Earnings release: Q4 2025
Fortress Biotech released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of t...
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Appro...
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on March 19, 2026.